Cholesterol-Years Score is Associated with Development of Senile Degenerative Aortic Stenosis in Heterozygous Familial Hypercholesterolemia

Tsuyoshi Nozue1, Masa-aki Kawashiri1, Toshinori Higashikata1, Atsushi Nohara2, Akihiro Inazu3, Junji Kobayashi4, Junji Koizumi5, Masakazu Yamagishi1, and Hiroshi Mabuchi2

1Molecular Genetics of Cardiovascular Disorders, Division of Cardiovascular Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
2Department of Lipidology, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
3Department of Health Science, Kanazawa University, Kanazawa, Japan.
4Department of Lifestyle-related Disease, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.
5Department of General Medicine, Kanazawa University Hospital, Kanazawa, Japan.

We retrospectively evaluated the frequency and identified the factors associated with the development of aortic stenosis (AS) in 96 patients with heterozygous familial hypercholesterolemia (FH). The frequency of AS was 31% (4/13) and that of critical stenosis was 15% (2/13) in older patients over the age of 70 years. All 4 patients with AS were female aged more than 70 years who were diagnosed with FH when aged more than 60 years. There were no significant differences in conventional coronary risk factors; however, the age at cardiac catheterization, age at diagnosis of FH and the cholesterol-years score (CYS) with AS were significantly higher than those without AS (p=0.006, p=0.017, p=0.021, respectively). In multiple regression analysis, CYS was a significant independent predictor for the development of AS (p=0.037) in 13 older patients over the age of 70 years. These results suggest that physicians should be aware that AS needs attention in older patients with heterozygous FH, especially women who have been diagnosed late in life and those who have been inadequately treated.


Key words: Familial hypercholesterolemia, Aortic stenosis, Cholesterol-years score, Statins

Introduction

Before 1950, rheumatic disease was considered to be the predominant cause of valvular aortic stenosis (AS). Acute rheumatic fever had virtually vanished by 1950, thus the number of patients with chronic rheumatic valvular AS was correspondingly low. Currently, two major causes of AS are considered, bicuspid aortic valve and degenerative calcific changes of tricuspid aortic valve1). Most of the risk factors of valvular AS are common to those of atherosclerotic cardiovascular disorders, such as hypercholesterolemia, hypertension, male sex and older persons2). Meta-analysis of 33 studies showed that 37% of coronary artery disease (CAD) was complicated with AS3). Conversely, patients with AS who needed aortic valve replacement surgery much more frequently possessed CAD that required bypass surgery1). The histological features of AS include calcification, fibrosis, and lipid deposition with morphological similarities to atherosclerosis4). This suggests that atherogenic factors may play an important role in the development of AS.

Familial hypercholesterolemia (FH) is a common autosomal dominant disorder caused by a mutation of the gene for the low-density lipoprotein (LDL) receptor5). FH is frequently associated with premature CAD,
and the rate of death from CAD among heterozygotes is several times higher than that among the general population. It has been proved that the increased use of lipid-lowering drugs, especially 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), has improved the prognosis of CAD; however, a recent double-blind, placebo-controlled study using 80 mg of atorvastatin showed no advantage of aggressive lipid-lowering therapy to halt the progression of AS.

Valvular and supra-valvular AS has been observed frequently in homozygous FH; however, little is known about the frequency and the factors associated with the development of AS in heterozygous FH. In the present study, we retrospectively evaluated the frequency and identified the factors associated with the development of AS in patients with heterozygous FH.

**Subjects and Methods**

**Subjects**

We retrospectively studied 96 consecutive patients with heterozygous FH (male/female = 66/30, mean age = 56 ± 13 years) who received elective cardiac catheterization between January 1990 and December 2000.

FH was diagnosed according to the following two criteria: (1) primary hypercholesterolemia patients (arbitrarily above 230 mg/dL in any age group) with tendon xanthomas, or (2) primary hypercholesteremic patients with and without tendon xanthomas in a first-degree relative of familial hypercholesterolemic patients. All the data of these patients were obtained before introducing lipid-lowering therapy.

AS was diagnosed according to the following two criteria: (1) presence of calcification and thickening of the aortic valve by B-Mode echocardiography, and (2) peak aortic jet velocity >2 m/s by continuous wave Doppler echocardiography. No patients had bicuspid aortic valve or a past history of rheumatic fever.

**Laboratory Determination**

Blood samples were obtained after overnight fasting. Serum cholesterol, triglyceride, and high-density lipoprotein (HDL) cholesterol levels were determined by standard enzymatic methods. LDL cholesterol was calculated by Friedewald's formula. Lp(a) was assayed by commercially available enzyme-linked immunosorbent assay (Tint Elize, Biopool, Sweden).

To estimate the lifelong total vascular exposure to profound hypercholesterolemia, the cholesterol-years score (CYS) was calculated as follows. The total cholesterol concentration (mg/dL) of each patient at the time of the original diagnosis was multiplied by the age of the patient at diagnosis. The total cholesterol concentration (mg/dL) of each patient after therapy was then multiplied by the years of treatment. The pretreatment and post-treatment cholesterol-years (mg-y/dL) were then added together for the total CYS.

**Echocardiography**

All patients were studied with B-Mode, M-Mode, Doppler (pulsed and continuous Mode) and color Doppler echocardiography using a Toshiba SSA-380A electronic scanner or Toshiba SSH-160A scanner with a 3.75 or 2.5 MHz transducer. We obtained an almost complete range of echocardiographic studies. Calcification and thickening of the aortic valve were assessed in short- and long-axis two-dimensional views.

**Cardiac Catheterization**

Coronary angiography was performed with multiple projection. Coronary angiograms were interpreted by at least 2 cardiologists without knowledge of the patient's clinical and laboratory findings. CAD was defined as the presence of a 50% or greater diameter reduction of at least 1 coronary artery. The extent and severity of stenotic changes were assessed by a score assigned to each of 15 segments according to the classification of the American Heart Association Grading Committee. A normal coronary angiogram was graded as 0, stenosis of less than 25% as 1, 25% to 50% stenosis as 2, 50% to 75% stenosis as 3, and more than 75% stenosis as 4. The coronary stenosis index (CSI) was defined as the sum of these scores, with a maximal value of 60.

Left ventriculography was performed and the

<table>
<thead>
<tr>
<th>Table 1. Baseline characteristics</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>56 ± 13</td>
<td></td>
</tr>
<tr>
<td>Sex (male/female)</td>
<td>66/30</td>
<td></td>
</tr>
<tr>
<td>HT (cm)</td>
<td>159.1 ± 10.1</td>
<td></td>
</tr>
<tr>
<td>BW (kg)</td>
<td>61.1 ± 10.5</td>
<td></td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.0 ± 2.8</td>
<td></td>
</tr>
<tr>
<td>Achilles tendon thickness rt (mm)</td>
<td>13 ± 5</td>
<td></td>
</tr>
<tr>
<td>lt (mm)</td>
<td>14 ± 5</td>
<td></td>
</tr>
<tr>
<td>At original diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TC (mg/dL)</td>
<td>330 ± 69</td>
<td></td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>256 ± 65</td>
<td></td>
</tr>
<tr>
<td>At cardiac catheterization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TC (mg/dL)</td>
<td>259 ± 53</td>
<td></td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>200 ± 52</td>
<td></td>
</tr>
</tbody>
</table>

HT, height; BW, body weight; BMI, body mass index; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol
pressure gradient across the aortic valve was measured in all patients. Thoratic aortography was performed in cases with AS by echocardiography.

**Statistical Analysis**

Statistical analysis was performed using Statview 5.0 software (SAS Institute Inc., Cary, North Carolina). All values are expressed as the mean ± SD. Differences between the means were compared with the unpaired t-test. The significance of any differences in proportions was tested with Chi-squared analysis. For stepwise multiple regression analysis, the nominal variable (hypertension, glucose intolerance, sex, and the presence of CAD) was included as well as numerical variables (total cholesterol levels at original diagnosis and at cardiac catheterization, body mass index, age at diagnosis of FH, CSI, and CYS). A statistically significant difference was defined as $p < 0.05$.

**Results**

Table 1 shows the baseline characteristics in this study. Sixty-six patients were male, and another 30 patients were female with a mean age of 56 ± 13 years. Mean total and LDL cholesterol levels at original diagnosis were 330 ± 69 mg/dL and 256 ± 65 mg/dL. Eight patients had been treated with only diet; 52 patients with statins alone, 12 patients with probucol alone, 9 patients with both statins and resins, 15 patients with both statins and probucol. Mean total and LDL cholesterol levels at cardiac catheterization significantly decreased to 259 ± 53 mg/dL and 200 ± 52 mg/dL, respectively.

Four patients were diagnosed with AS. Table 2 shows the clinical characteristics of 4 patients with AS. All were female aged more than 70 years who were diagnosed with FH when aged more than 60 years. Table 3 shows the summary of cardiac-catheterization findings of patients with AS. None had supra-valvular AS, nor ostial coronary stenosis. Two patients showed critical stenosis >50 mmHg of pressure gradient.

As all 4 patients with AS were female, we compared the clinical characteristics of 30 women in order to evaluate the factors associated with the development of AS (Table 4). There were no significant differences in conventional coronary risk factors such as total and LDL cholesterol levels, fasting plasma glucose, immunoreactive insulin, Lp(a), homocysteine, or systolic and diastolic blood pressure. However, the age at cardiac catheterization, age at diagnosis of FH and the CYS with AS were significantly higher than in those without AS ($p = 0.006$, $p = 0.017$, $p = 0.021$, respectively).

To balance the contribution from aging, multiple regression analysis was performed using 10 variables: total cholesterol levels at original diagnosis and at cardiac catheterization, hypertension, glucose intolerance, body mass index, sex, age at diagnosis of FH, presence of CAD, CSI, and CYS in 13 elder patients over the age of 70 years. In this analysis, CYS was a significant ($p = 0.037$) independent predictor for the development of AS (Table 3). When we performed multiple regression analysis except for this CYS, female sex was an independent but not significant ($p = 0.0642$) factor for the development of AS (data not shown).

**Discussion**

In our study, the frequency of AS was 31% (4/13)
Clinical characteristics of patients with and without aortic stenosis in 30 women

<table>
<thead>
<tr>
<th>Variable</th>
<th>AS (+) (n = 4)</th>
<th>AS (-) (n = 26)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>75 ± 3</td>
<td>61 ± 9</td>
<td>0.006</td>
</tr>
<tr>
<td>Age at diagnosis of FH (years)</td>
<td>66 ± 4</td>
<td>51 ± 12</td>
<td>0.017</td>
</tr>
<tr>
<td>Onset of CAD (years)</td>
<td>71 ± 5</td>
<td>62 ± 6</td>
<td>0.047</td>
</tr>
</tbody>
</table>

at original diagnosis

| TC (mg/dL)         | 351 ± 52 | 355 ± 79 | 0.936 |
| LDL-C (mg/dL)      | 278 ± 41 | 275 ± 84 | 0.933 |

At cardiac catheterization

| TC (mg/dL)         | 232 ± 17 | 267 ± 53 | 0.204 |
| LDL-C (mg/dL)      | 174 ± 14 | 207 ± 54 | 0.239 |
| FPG (mg/dL)        | 95 ± 21  | 105 ± 41 | 0.624 |
| IRI (IU/L)         | 5.2 ± 1.0| 7.9 ± 3.2| 0.119 |
| Lp(a) (mg/dL)      | 15.5 ± 13.2| 25.3 ± 15.3| 0.347 |
| Hcy (mg/dL)        | 9.8 ± 2.1| 10.0 ± 7.4| 0.969 |
| SBP (mmHg)         | 133 ± 23 | 123 ± 18 | 0.338 |
| DBP (mmHg)         | 70 ± 13  | 70 ± 10  | 0.961 |
| CSI                | 22 ± 10  | 15 ± 12  | 0.291 |
| CYS (mg-y/dL)      | 25115 ± 3538| 20238 ± 3746| 0.021 |

Table 4. Clinical characteristics of patients with and without aortic stenosis in 30 women

<table>
<thead>
<tr>
<th>Step Variable</th>
<th>Coefficient</th>
<th>SE</th>
<th>F Value</th>
<th>Adjusted R²</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 CYS</td>
<td>7.9</td>
<td>3.3</td>
<td>5.7</td>
<td>0.28</td>
<td>0.037</td>
</tr>
</tbody>
</table>

Multiple regression analysis was performed using 10 variables: total cholesterol level at original diagnosis and at cardiac catheterization, hypertension, glucose intolerance, body mass index, sex, age at diagnosis of FH, presence of coronary artery disease, coronary stenosis index, and cholesterol-years score. Hypertension, glucose intolerance, male and presence of coronary artery disease were assigned values of 1. Normotension, normal glucose intolerance, female and no presence of coronary artery disease were assigned values of 0.

and that of critical stenosis was 15% (2/13) in older patients over the age of 70 years. It is known that age contributes to degenerative thickening of the aortic valve in the general population and may lead to valvular AS. Lindroos et al. reported that the prevalence of at least moderate valvular AS was about 5% and that of critical stenosis was about 3% in 501 of the general population aged 75 to 86 years. Aronow et al. reported that the prevalence of severe valvular AS was 2% in 781 unselected elderly patients in a health care facility. Compared with these data, the prevalence of AS in older patients with heterozygous FH was higher than that of previous studies suggesting that hypercholesterolemia might be an increased risk factor for the development of AS.

Table 5. Stepwise multiple regression coefficients, F values, and adjusted R² for the development of aortic stenosis in 13 older patients

Our data showed that CYS was a significant independent predictor for the development of AS. Ralli et al. showed a significant positive correlation between the mean gradient across the aortic valve and total CYS in heterozygous FH. This correlation indicates that lifelong exposure to high cholesterol concentrations accelerated age-related degeneration of the aortic valve; therefore, it would be necessary to start lipid-lowering therapy early in life and to control cholesterol level adequately.

The mean age of death in heterozygous FH men and women was 54 and 65 years, respectively. Many clinical trials have shown that statins can significantly reduce the incidence of CAD in both primary and secondary prevention; thus, statins revolutionized the prognosis of CAD in hypercholesterolemic patients. However, mortality from CAD in statin-treated patients with FH is 2.5 to 2.6-fold higher than in the general population. This mortality risk is highest in middle-aged men. On the other hand, female FH patients have no increased mortality from CAD compared to the general population. Interestingly, this sex difference, which is also a characteristic feature of the usual form of CAD in the general population, does not seem to be operative in homozygous FH.
Estrogens have been reported to provide protection against CAD in postmenopausal women. In consideration of our data, there is some possibility that the anti-atherogenic effects of estrogens are attributed to senile degenerative aortic valve stenosis in these postmenopausal female patients.

In previous reports, statins had reduced progression of AS and were associated with slower progression of AS; however, there was no association between the progression of AS and the cholesterol level. A recent randomized trial of intensive lipid-lowering therapy did not halt the progression of AS. AS is common in younger patients with homozygous FH and it appears that they are exposed to high cholesterol concentrations early in life. Conversely, AS occurs only in cases of severe and prolonged hypercholesterolemia in heterozygous FH. Thus, both the cholesterol level and duration affect the development of AS in heterozygous FH.

Conclusions

In conclusion, CYS was a significant independent predictor for the development of senile degenerative AS in heterozygous FH. Physicians should be aware that AS needs attention in older patients with heterozygous FH, especially in women who have been diagnosed late in life and those who have been inadequately treated. Further studies are necessary to discover the mechanisms and factors for the prediction of senile degenerative AS.

Study Limitations

There are some limitations regarding the interpretation of these results and drawing conclusions from a case series. First, a relatively small number of patients eligible for analysis in this cohort study makes it difficult to generalize or to apply the results to other patient populations. Second, all patients in this study were examined by a cardiologist, who decided that elective cardiac catheterization was indicated. Third, there will be a survivor bias since the most severely affected patients may have died at home, and were inevitably excluded.

Acknowledgements

We express our special thanks to Mayumi Yoshida, Mihoko Mizuno, and Sachio Yamamoto for their outstanding technical assistance. We are grateful to Dr. Ichiro Michishita (Division of Cardiology, Department of Internal Medicine, Yokohama Sakae Kyo- sai Hospital) for advice in preparing this manuscript.

References

3) Mautner GC and Roberts WC: Reported frequency of coronary arterial narrowing by angiogram in patients with valvular aortic stenosis. Am J Cardiol, 1992; 70:539-540
9) Scientific Steering Committee on behalf of the Simon Broome Register Group: Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Atherosclerosis, 1999; 142:105-112


19) Waller BF and Roberts WC: Cardiovascular disease in the very elderly. Analysis of 40 necropsy patients aged 90 years or over. Am J Cardiol, 1983; 51:403-421


